Abstract
Subject Index
A549 tumor tissues, 386–397
Absorption spectrophotometry, atomic, 270–276
Absorption spectroscopy, 258–268
Acute brain injury, 434–445
Acute lung inflammation, 398–405
Adenomatous polyposis coli (APC) genes, 305–315
Adenoviral vector, rBMSC transfection via, 227–236
α2β1 integrin-targeted peptide probes, 284–293
αvβ3 integrins
3D ultrasonography and, 460–468
as cancer imaging target, 123–133
99mTc-3P-RGD2 monitoring, 386–397
RGD-Cy5.5 optical probe and, 469–480
Angiogenesis, 3D ultrasonography of, 460–468
Anionic microparticles, 43–55
Annexin A5 SPECT/PET radionuclides, 340–358
Antibodies, in developing imaging probes, 407–419
Anticancer drugs, poly(
Anti–epidermal growth factor receptor therapy, 153–166
Anti-prostate stem cell antigen (PSCA) diabody (A2 Db), 168–175
Antitumor activity
of PG-TXL, 28–39
of sigma-2 receptors, 420–433
Apoptosis imaging, 340–358
ApoSense family, 340–358
Aptamers, imaging probes and, 407–419
Asp-Gly-Glu-Ala (DGEA)-based optical agents, 284–293
Asymmetric cyanine dyes, 258–268
Atherosclerosis, 238–246
Atomic absorption spectrophotometry (AAS), 270–276
ATP-binding cassette (ABC) transporters, 215–225
Autoradiography, 227–236
B subunit of Shiga toxin, 135–142
Bacterial cytosine deaminase (bCD) protein, 359–369
β-emitting radionuclides, 177–185
Bimodal agents, for integrated FMI/MRI lymphography, 317–326
Biodistribution
of asymmetric cyanine dyes, 258–268
of inorganic nanoparticles, 2–14
NIR imaging of S1MP, 56–67
of porous silicon microparticles, 43–55
Bioinformatics analysis, integrated, 123–133
Bioluminescence imaging (BLI)
of apoptosis in oncology, 340–358
detecting long-term transgene brain activity, 327–339
gLuc vs. fLuc, 377–385
improving spatial resolution in, 446–452
monitoring cyclophosphamide therapy with, 278–283
of neuronal responses to injury/repair, 434–445
Biomolecules, microfluidic-based 18F-labeling of, 168–175
Blind deconvolution restoration method, 446–452
Blood assays, gLuc, 377–385
Blood-brain barrier (BBB) penetration, 91–101
Blood-nerve barrier (BNB) penetration, 91–101
BMB (4,49-[(2-methoxy-1,4-phenylene)di-(1E)-2,1-ethenediyl]bis-benzenamine) contrast agent, 91–101
Bone mesenchymal stem cells (BMSCs), 227–236
Brain
ischemia, 434–445
transgene activity in, 327–339
tumors, 453–459
Breast cancer
breast density and, 370–376
microcalcification, 295–303
Breast density (BD), 370–376
BT-474 (HER2/neu-positive) tumors, 177–185
Calcification-specific contrast agents, 295–303
Cancer
breast, 295–303, 370–376
colorectal, 305–315
liver, 69–76
medullary thyroid, 144–151
noninvasive imaging of, 123–133, 284–293
ovarian, 248–253
pancreatic, 153–166
promyelocytic leukemia, 81–89
prostate, 168–175, 284–293
therapeutics, 28–39
in vivo imaging of apoptosis, 340–358
Cannabinoid type 1 (CB1) receptor system, 481–487
Caspase activation, 340–358
Cationic microparticles, 43–55
Cell death imaging, 340–358
Cell proliferation, 420–433
Cell surface-bound targets, 123–133
Cell transplantation, 359–369
Cellular interactions, of porous silicon microparticles, 43–55
Cellular iron content, 270–276
Central nervous system (CNS) neuronal plasticity, 434–445
Cerenkov luminescence imaging (CLI), 177–185
Cervical nerve root compression, 206–213
Cetuximab, 153–166
Chemokine receptor 4 (CXCR4), 248–253
Cholecystokinin-2 (CCK2)/gastrin receptor-positive tumors, 144–
151 Chromatin condensation, 340–358
Chronic obstructive pulmonary disease (COPD), 398–405
Cigarette smoke exposure (CSE), 398–405
Click beetle luciferase (cLuc)-BLI intensity, 215–225
Coelenterazine-based bioluminescence imaging (BLI), 215–225
Colorectal carcinoma, 305–315
Combined cetuximab and irinotecan, 153–166
Combined imaging-drug delivery approach, 238–246
Combined PET-MRI-based assessment, 453–459
Computed tomographic colonography (CTC), 305–315
Computed tomography (CT), 295–303
Confocal laser scanning microscopy (CLSM), 111–120, 197–204
Conjugate 1, multimodal imaging probe, 359–369
Contrast agents
assessing cyanine dyes as, 258–268
calcification-specific, 295–303
magnetic nanoparticles as, 102–109
microbubble, 135–142, 238–246, 460–468
nerve-specific, 91–101
NIR imaging of CysLT1R with, 81–89
polyp-specific Rh-I-UEA-1 liposomes, 305–315
spectroscopically well-characterized, 469–480
SPIO nanoparticles, 206–213, 340–358
STxB microbubbles, 135–142
See also Imaging agents
Cortex, transgene activity, 327–339
Cross-linked iron oxide (CLIO), 4
Curated interaction databases, 123–133
Cyclic RGD peptides, 99mTc-labeled, 386–397
Cyclophosphamide (CTX) therapy, 278–283
Cysteinyl leukotriene receptor 1 (CysLT1R), 81–89
Cytoreductive surgery, 248–253
Cytotoxicity, of inorganic nanoparticles, 2–14
Dansylhydrazone (DNFSH), 340–358
Deoxyribonucleic acid (DNA) nanoparticles, 327–339
Detection sensitivity, of RGD-Cy5.5
optical probe, 469–480
Development, of imaging agents, 407–419
DGEA (Asp-Gly-Glu-Ala)-based optical agents, 284–293
Diabody-based tracers, 168–175
Dialysis, for protein binding assessment, 258–268
Diffusion-weighted imaging (DWI), 153–166
Digital microfluidic droplet generation (DMDG) chip, 168–175
D-luciferin-based bioluminescence imaging (BLI), 215–225
DNA fragmentation, in apoptosis imaging, 340–358
DNA nanoparticles (DNPs), 327–339
Double-labeling probe, Conjugate 1, 359–369
Drug delivery
cellular associations/biodistribution and, 43–55
image-guided microbubble-based, 238–246
poly(
Dual-modality molecular imaging, 278–283
See also Multimodality molecular imaging
Dual-reporter imaging
gLuc and fLuc for, 377–385
of neuronal responses, 434–445
Dye-protein binding, 258–268
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), 153–166
Ear edema, 81–89
Early therapeutic assessment approach, DCE-MRI for, 153–166
Echo-planar spectroscopic imaging (EPSI), 187–195
89Zr-DFO-trastuzumab, 177–185
[11C]JHU75528 radio tracer, 481–487
[11C]-methionine positron emission tomography (MET-PET), 453–459
Emission spectra, of sigma-2 receptors, 420–433
Emphysema, FMI detection of, 398–405
Endothelial progenitor cells (EPCs), 359–369
Environmental issues, of nanoscale materials, 17–25
Epidermal growth factor receptor (EGFR) in aggressive tumor growth, 153–166
as cancer imaging target, 123–133
as tumor-targeting agent in EOC, 248–253
Epithelial ovarian cancer (EOC), 248–253
Erlotinib, 153–166
Erythroblastic leukemia viral oncogene homologue 2 (ERRBB2/HER2), 123–133
Exact cone beam algorithm (ECBA), 295–303
Excitation spectra, of sigma-2 receptors, 420–433
Fast cone beam algorithm (FCBA), 295–303
Federal initiatives, for nanomaterial governance, 21–22
Firefly luciferase gene (fLuc)
ABC transporter effect, 215–225
for BLI tumor monitoring, 377–385
for stem cell imaging, 111–120
First-stage microparticles (S1MPs), 56–67
FLARE™ intraoperative NIRF imaging system, 91–101
Florid epithelial hyperplasia (FEH), 370–376
Fluorescence molecular imaging (FMI)
for early detection of COPD, 398–405
integrated lymphography using, 317–326
of neuronal responses to injury/repair, 434–445
with OCT, of adenomatous polyps, 305–315
Fluorescent microscopy, 111–120
Fluorescent sigma-2 receptor ligands, 420–433
Fluorine 18 (18F)-labeled biomolecules, 168–175
Fluoro-optical molecular imaging, 258–268
Fluorophores
hemicyanine, DY-734, 81–89
nerve-highlighting, 91–101
substitution pattern of, 258–268
Folate hydrolase, prostate-specific
membrane antigen (FOLH1/PSMA), 123–133
Folate receptor 1, adult (FOLR1/FBP), 123–133
Folate receptor α, 248–253
Fourier transform infrared spectroscopy (FTIR), 43–55, 56–67
Gadofluorine 8, 317–326
GAP-43-luc/gfp reporter mice, 434–445
Gastrin receptor scintigraphy, 144–151
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), 144–151
Gaussia luciferase gene (gLuc), 215–225, 377–385
Gb3 glycolipid overexpression, 135–142
GE3082 (4-[(1E)-2-[4-[(1E)-2-[4-aminophenyl]ethenyl]-3-methoxyphenyl]ethenyl]-benzonitrile), 91–101
Gel electrophoresis, 258–268
Gemcitabine, 153–166
Genomic profiles, 123–133
Gliomas
HSV-1 vector–mediated gene expression, 197–205
imaging of apoptosis in, 340–358
PET-MRI with MET assessment of malignant, 453–459
See also Tumor(s)
Glycolipid overexpression, 135–142
Glypican-3 (GPC3) expression, 69–76
Gold nanoparticles (AUNPs), 2–14
Governance strategies, for nanotechnology, 17–25
Growth-associated protein-43 (GAP-43), 434–445
Health issues, of nanoscale materials, 17–25
Hematopoietic stem cell (HSC) imaging technologies, 111–120
Hemicyanine fluorophore DY-734, 81–89
Hepatocellular carcinoma (HCC), 69–76
Hepsin, transmembrane protease, serine 1 (HPN), 123–133
HER2/neu-positive tumors, 177–185
Herpes simplex virus type 1 (HSV-1)
amplicon vector–mediated gene expression, 197–204
High spectral and spatial resolution magnetic resonance imaging (HiSS MRI), 187–195
High-resolution computed tomography (CT), 295–303
Histology, in tumor angiogenesis monitoring, 187–195
HL-60 human promyelocytic leukemia cells, 81–89
Homologous recombination (HR)-mediated gene targeting, 111–120
HSV-1 virions expressing green fluorescent protein (HSV-GFP), 197–204
HT29 tumor tissues, 386–397
Human embryonic stem (hES) cell imaging technologies, 111–120
Human Gli36 glioma spheroids, 197–204
Human iodide symporter (hNIS) gene, 227–236
Human prostate cancer xenograft, 168–175
Human serum albumin (HSA), 2–14
Hydrophilic cyanine dyes, 258–268
Hydroxyapatite (HA), 295–303
Hypovascular pancreatic adenocarcinoma, 153–166
Image fusion, in integrated FMI/MRI lymphography, 317–326
Image quantification improvements, 481–487
Image restoration method, 446–452
Image-guided surgery, with CLI, 177–185
Imaging agents
Conjugate 1 as multimodal, 359–369
optical, radioactive probes as, 177–185
PG conjugates as, 28–39
techniques for developing, 407–419
See also Contrast agents
Immuno-positron emission tomography (immunoPET), 168–175
In vivo bioluminescence imaging, 434–445, 446–452
See also Bioluminescence imaging (BLI)
In vivo Cerenkov luminescence imaging, 177–185
In vivo fluorescence imaging, 434–445
See also Fluorescence molecular imaging (FMI)
In vivo NIR imaging. See Near-infrared fluorescence (NIRF) imaging
Induced pluripotent stem (iPS) cell imaging technologies, 111–120
Infarcted myocardium, 227–236
Infection vs. vector injection, of HSV-GFP vectors, 197–204
Inflammatory diseases, 81–89
Initiatives, for nanotechnology regulation, 17–25
Inorganic nanoparticles, for multimodal imaging, 2–14
Integrated bioinformatics analysis of genomic profiles, 123–133
Integrated FMI/MRI lymphography, 317–326
Intraoperative CLI-guided surgery, 177–185
Intraoperative fluorescence imaging, 248–253
Intraperitoneal tumors, 144–151
Intravascular delivery, of therapeutic/imaging agents, 43–55
Invasive ductal carcinoma (IDC), 370–376
Irinotecan, cetuximab and, 153–166
Iron content quantification, 270–276
Kinetic internalization, of sigma-2 receptors, 420–433
Knockout mice, CB1 receptor system of, 481–487
Labeling techniques, stem cell research, 111–120
Large blood vessels, drug delivery in, 238–246
Lectin-mediated polymerized targeted liposomes, 305–315
Lifetime-gated NIRF imaging, 469–480
Live imaging, of neuronal responses, 434–445
Liver cancer, 69–76
Long-term transgene brain activity, 327–339
Luciferase-based bioluminescence imaging (BLI)
ABC transporter affect on, 215–225
of long-term transgene activity, 327–339
Lung disease susceptibility, 398–405
Lymphography, integrated FMI/MRI, 317–326
Lysomal localization, of sigma-2 receptors, 420–433
Magnetic nanoprobes, 102–109
Magnetic resonance imaging (MRI) of apoptosis, 340–358
cell tracking with, 270–276
high spectral/spatial resolution, 187–195
inorganic nanoparticles for, 2–14
integrated lymphography using, 317–326
of malignant gliomas, 453–459
NIRF imaging and, 359–369
PG conjugates for, 33–35
SPIO-enhanced, 206–213
Magnetic resonance spectroscopy (MRS), 340–358
Magnetically labeled cells, 270–276
Magneto-motive ultrasound (MMUS) imaging, 102–109
Mammographic breast density, 370–376
Margin status assessment, 177–185
Matrix metalloproteinase (MMP), 248–253, 398–405
MDA-MB-435 tumor tissues, 386–397
Medullary thyroid carcinoma, 144–151
Membrane-bound targets, 123–133
Metabolism mechanisms, of inorganic nanoparticles, 2–14
MET-PET and MRI assessment, 453–459
Microbubble contrast agents
in 3D ultrasonography, 460–468
STxB-functionalized, 135–142
ultrasonography with, 238–246
Microcalcification, breast cancer, 295–303
Micro-computed tomography (microCT)
of adenomatous polyps, 305–315
of tumor vasculature, 187–195
Microfluidic-based 18F-labeling, 168–175
Microparticles, porous silicon, 43–55, 56–67
MicroPET imaging, 168–175
Middle cerebral artery occlusion (MCAO), 434–445
Mild epithelial hyperplasia (MEH), 370–376
Mixed ductal carcinoma in situ with invasive ductal carcinoma (DCIS + IDC), 370–376
Molecular imaging probe development, 407–419
Molecular optical imaging, 1, 258–268
MRI with MET-PET assessment, 453–459
MRI-NIRF imaging probe, 2–14
MRI-PET imaging probe, 2–14
Mucin-1, cell surface associated (MUC1), 123–133
Multicellular spheroid (MCS) model, of human glioma cells, 197–204
Multifunctional nanoparticles, 69–76
Multifunctional synthetic PG-based cancer therapeutic/imaging agents, 28–39
Multimodality molecular imaging of endothelial progenitor cells, 359–369
with FMI/MRI lymphography, 317–326
inorganic nanoparticles and, 2–14
PG for, 36–39
of tumor response to CTX therapy, 278–283
Multiphoton microscopy, 111–120
Multiple targeted anticancer agents, 28–39
Multispectral optical imaging (MSI), 305–315
Multistage nanovector delivery system, 56–67
Murine lymphatic system, 317–326
Mutated adenomatous polyposis coli (APC) genes, 305–315
Myelinated nerve staining, 91–101
Myocardium infarction, 227–236
Nano Risk Framework, 23–24
Nanomaterial governance systems, 17–25
Nanomedicine, 1
Nanoparticles (NPs)
deoxyribonucleic acid, 327–339
inorganic, for multimodal MI, 2–14
pMMUS imaging of magnetic, 102–109
porous silicon biodistribution, 56–67
targeting HCC cells, 69–76
Nanoporous silicon microparticles, 56–67
Near-infrared fluorescence (NIRF) imaging
of α2β1 integrin expression, 284–293
of apoptosis in oncology, 340–358
CysLT1R detection with, 81–89
for evaluating nanovector biodistribution, 56–67
intraoperative, in ovarian cancer, 248–253
lifetime-gated, 469–480
of magnetic nanoprobes, 102–109
MRI and, 359–369
nerve-specific contrast agents for, 91–101
Nerve-highlighting fluorophores, 91–101
Neurite outgrowth, 434–445
Neuroendocrine tumors, 144–151
Neuroinflammation, 206–213
Neuronal responses to injury/repair, 434–445
99mTc-3P-RGD2 radiotracer, 386–397
99mTc-HYNIC-annexin A5 radioligand, 340–358
99mTc-pertechnetate radionuclide, 227–236
99mTc(V)-DMSA radiotracer, 370–376
Noninvasive imaging
of α2β1 integrin expression, 284–293
of apoptosis, 340–358
of bone mesenchymal stem cells, 227–236
of cancer, 123–133
PG conjugates and, 28–39
RGD-Cy5.5 optical probe and, 469–480
in stem cell research, 111–120
Nonviral gene therapy technique, 327–339
Novel transgenic tool, assessing brain regenerative responses, 434–445
N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB), 168–175
Oncology, apoptosis in, 340–358
Optical coherence tomography (OCT), 305–315
Optical imaging poly(L-glutamic acid) for, 35–36
using Cerenkov radiation, 177–185
Optimization, probe, 407–419
Orthotopic pancreatic tumor xenografts, 153–166
Ovarian cancer, 248–253
Paclitaxel, 28–39
Pain, radicular, 206–213
Pancreatic cancer, 153–166
PC-3 tumor tissues, 386–397
Peptides, as imaging agents, 407–419
Peripheral blood mononuclear cells (PBMCs), 270–276, 420–433
PET-MRI with MET assessment, 453–459
PG-paclitaxel (PG-TXL), 28–39
Phage display, for screening peptides, 407–419
Phosphatidylserine (PS) externalization, 340–358
Photothermal/photoacoustic contrast agents, 11–12
Plasminogen activator, urokinase receptor (PLAUR/uPAR), 123–133
Pluripotent stem cell imaging technologies, 111–120
Point spread function (PSF), 446–452
Poly(
Poly-
Polymeric drug delivery systems, 28–39
Polymerized targeted liposomes, 305–315
Polyps, adenomatous, 305–315
Pool-and-split technique, 407–419
Porous silicon microparticles, 43–55, 56–67
Positron emission tomography (PET) of apoptosis, 340–358
of brain CB1 receptor system, 481–487
cyclophosphamide therapy and, 278–283
of malignant gliomas, 453–459
68Ga-DOTA-MG0 tracer, 144–151
Postsurgical neuralgia, 91–101
Probe optimization, 407–419
Product liability, in nanotechnology, 17–25
Proliferation probes, 420–433
Proliferation-seeking radiotracer
99mTc(V)-DMSA, 370–376
Prostate cancer
α2β1 integrin-targeted probes, 284–293
18F-labeling of biomolecules for, 168–175
Protein-protein interaction networks, 123–133
Proteomic analysis, of serum opsonins, 43–55
Public cancer microarray database, 123–133
Pulsed magneto-motive ultrasound (pMMUS) imaging, 102–109
Pure invasive ductal carcinoma (IDC), 370–376
Quantum dots (QDs)
fluorescence imaging using, 317–326
multifunctional probes based on, 2–14
for stem cell imaging, 111–120
Radicular pain, 206–213
Radiolabeled amino acids, 453–459
Radiolabeled caspase inhibitors, 340–358
Radioligands imaging, 340–358
Radiotherapy, PG-TXL and, 28–39
Radiotracer tumor uptake, 386–397
Raman spectroscopy, 11–12
Rat bone mesenchymal stem cells (rBMSCs), 227–236
Rat sodium iodide symporter (rNIS) gene, 227–236
Real-time imaging-drug delivery approach, 238–246
Real-time pMMUS imaging, 102–109
Regulatory agencies, for nanomaterial governance, 17–25
Renilla luciferase (rLuc)-BLI intensity, 215–225
Responsible NanoCode, 24–25
Restoration, of bioluminescent images, 446–452
RGD-Cy5.5 optical probe, 469–480
Rh-I-UEA-1 polymerized liposomes, 305–315
Rimonabant pretreatment, 481–487
Risk management, of nanoscale materials, 17–25
Safety issues, with nanoscale materials, 17–25
Scintigraphy, gastrin receptor, 144–151
Screening techniques, for imaging agents, 407–419
Second-stage theranostic nanoparticles (S2NPs), 56–67
Sentinel lymph node (SLN) mapping, 36–37
Serum opsonization, 43–55
Serum protein binding, 258–268
Shiga toxin B subunit, 135–142
Sigma-2 receptor ligands, 420–433
Silica nanoparticles, 2–14
Silicon microparticles
NIR imaging of biodistribution, 56–67
serum opsonization of, 43–55
Simultaneous nerve and vessel imaging, 91–101
Single breast cancer microcalcification, 295–303
Single-photon emission computed tomography (SPECT)
of apoptosis, 340–358
monitoring of transplanted rBMSCs, 227–236
Single-walled carbon nanotubes (SWCNTs), 11–12
68Ga-DOTA-minigastrin (MG0) PET tracer, 144–151
Small molecules, for imaging probes, 407–419
Small-animal PET, 278–283
Small-molecular-weight therapeutics, 28–39
Somatostatin receptor
as cancer imaging target, 123–133
scintigraphy, for tumor detection, 144–151
Spatial resolution, in BLI, 446–452
Spectrophotometry, 270–276
Spectroscopically well-characterized RGD optical probe, 469–480
Spectroscopy, Fourier transform infrared, 43–55, 56–67
Stem cell(s)
bone marrow mesenchymal, 227–236
imaging technologies, 111–120
transplanted, 359–369
Striatum, transgene activity in, 327–339
Stroke, proregenerative signals after, 434–445
STxB-functionalized microbubbles, 135–142
Subcellular localization, of sigma-2
receptors, 420–433
Subcutaneous tumors, 144–151
Substantia nigra, 327–339
Sulfonate groups, 258–268
Summit, exploring nanomedicine, 1
Superparamagnetic iron oxide (SPIO) nanoparticles
HiSS data acquired with, 187–195
multifunctional probes based on, 2–14
pMMUS imaging of, 102–109
quantifying iron content in, 270–276
Superparamagnetic iron oxide (SPIO)-enhanced MRI, 206–213
Surgical procedures
intraoperative CLI-guided, 177–185
nerve damage during, 91–101
SW116 sigma-2 receptor ligand, 420–433
SW120 sigma-2 receptor ligand, 420–433
Synaptogamin I protein, 340–358
Synthetic biocompatible polymers, 28–39
T1-weighted MRI, 359–369
Target selection, in probe development, 407–419
Targeted anticancer agents, 28–39
Targeted microbubbles, 238–246
Targeted microinjections, 197–204
Technetium 99m pentavalent dimercaptosuccinic acid (99mTc(V)-DMSA), 370–376
Three-dimensional human Gli36 glioma spheroids, 197–204
Three-dimensional ultrasonography, 460–468
Time-lapse imaging technology, 111–120
Time-resolved NIRF imaging, 469–480
Tissue scattering, in BLI, 446–452
Toxic Substances Control Act (TSCA), 17–25
Tracers. See Contrast agents; Imaging agents
Transduction efficiency of HSV-GFP, 197–204
Transfected bone marrow mesenchymal stem cells, 227–236
Transgene activity in brain, 327–339
Transgenic mice, 434–445
Transient nerve root compression, 206–213
Transplanted embryonic stem cell imaging technologies, 111–120
Transplanted stem cells, 359–369
Transport molecules, BLI intensity and, 215–225
Tumor(s)
3D ultrasonography of, 460–468
angiogenesis, 135–142, 187–195
cyclophosphamide therapy for, 278–283
gLuc BLI monitoring of, 377–385
lifetime-gated imaging of, 469–480
PG-TXL and, 28–39
sigma-2 ligands targeting, 420–433
targeting agents in EOC, 248–253
targeting with multifunctional NPs, 69–76
See also Gliomas
Two-dimensional fluorescence reflectance imaging, 317–326
Two-dimensional gel electrophoresis (2DGE), 43–55
U87MG glioma cells, 386–397
Ultrafiltration, in protein binding assessment, 258–268
Ultrasmall magnetic nanoparticles, 102–109
Ultrasound imaging
3D, of angiogenesis, 460–468
of Gb3-expressing tumor cells, 135–142
pulsed magneto-motive, 102–109
with targeted microbubbles, 238–246
US Environmental Protection Agency (EPA), 17–25
Vascular endothelial growth factor (VEGF), 248–253
Vascular pathology, 238–246
Vector application assessment, of HSV-GFP, 197–204
Wild-type mice, CB1 receptor system, 481–487
Zymosan A–induced ear edema, 81–89
Author Index
Abad, Sergio, 481
Adelstein, S. James, 123
Akkoul, Smaïl, 446
Alves, Frauke, 469
Amra, Sarah, 43
An, Rei, 227
Antsaklis, Aris, 370
Archontaki, Aikaterini, 370
Ashitate, Yoshitomo, 91
Barnhardt, Nicole E., 91
Béhé, Martin, 144
Bergeson, Lynn L., 17
Bhavane, Rohan, 56
Blanco, Elvin, 43
Blasberg, Ronald G., 215
Boerman, Otto C., 144
Boersma, Hendrikus H., 340
Böhm, Ingrid, 270
Brehm, Robert, 258
Brom, Maarten, 144
Buchsbaum, Donald J., 153
Burokas, Aurelijus, 481
Busch, Corinna, 81
Cai, Hancheng, 284
Cao, Wei, 227
Chakraborty, Sudipta, 386
Chang, Katherine C., 420
Chen, Chao-Wei, 305
Chen, Xiaoyuan, 3
Chen, Yi-Chun, 168
Chen, Yu, 305
Cheng, Linzhao, 111
Chiappini, Ciro, 56
Cliby, William A., 248
Conti, Peter S., 284
Cooper, Mark J., 327
Couture, Olivier, 135
Crane, Lucia M.A., 248
Czupryna, Julie C., 206
Dayton, Paul A., 460
De Spiegeleer, Bart, 340
Decaudin, Didier, 135
Dehay, Sabrina, 135
del Puerto-Nevado, Laura, 398
Dowdy, Sean C., 248
Dransart, Estelle, 135
Dullin, Christian, 469
Dunkl, Veronika, 453
Elsinga, Philip H., 340
Emelianov, Stanislav Y., 102
Fan, Xiaobing, 177
Fang, Chen, 69
Feingold, Steven, 460
Ferrari, Mauro, 43, 56
Fineberg, Naomi S., 153
Fink, Gereon R., 453
Fischer, Dagmar, 258
Fish, Kenneth M., 91
Fletcher, Anita M., 327
Folks, Karri D., 153
Fothiadaki, Athina, 370
Foxley, Sean, 177
Fraefel, Cornel, 197
Frangioni, John V., 79, 91, 295
Frank, Wilhelm, 258
Fujii, Hirofumi, 295
Galldiks, Norbert, 453
Gao, Haijuan, 386
Gao, Qiujuan, 278
Gao, Zairong, 227
George, James F., 153
Gessner, Ryan C., 460
Gibbs-Strauss, Summer L., 91
Gispert, Juan Domingo, 481
Godin, Biana, 56
Goldberg, Mark P., 420
González-Mangado, Nicolás, 398
Gotthardt, Martin, 144
Grabolle, Markus, 258
Gravel, Mathieu, 434
Griffiths, Gary L., 305
Grimm, Jan, 177
Grizzle, William E., 153
Guo, Feng, 168
Guo, Lingling, 153
Haishi, Tomoyuki, 317
Hamann, Franziska M., 258
Han, Dong, 278
Haney, Chad R., 177
Harba, Rachid, 446
He, Yong, 227
Herance, Raúl, 481
Hescheler, Jürgen, 197
Hesterman, Jacob, 295
Hilger, Ingrid, 81, 258
Holland, Jason P., 177
Hoppin, Jack, 295
Hossack, John A., 238
Hotchkiss, Richard S., 420
Hu, Jia, 227
Hu, Shuo, 227
Huang, Chiun-Wei, 284
Huang, Ruimin, 215
Hyrc, Krzysztof, 420
Inoue, Kazumasa, 295
Inoue, Yusuke, 317, 377
Izawa, Kiyoko, 377
Jacobs, Andreas Hans, 197, 453
Jang, Yoon-Young, 111
Jiménez, Xavier, 481
Johannes, Ludger, 135
Johnson, Bruce F., 91
Jones, Lynne A., 420
Joosten, Lieke, 144
Ju, Shenghong, 359
Kaestle, Christine, 197
Kaiser, Werner A., 81, 258
Karczmar, Gregory S., 177
Karianos, Theodore, 370
Kassis, Amin I., 123
Kaytor, Michael D., 327
Kelly, Kimberly A., 407
Kessler, Horst, 469
Khullar, Onkar, 91
Kievit, Forrest M., 69
Kim, Hyunki, 153
Kim, Young-Seung, 386
Kiryu, Shigeru, 317, 377
Klibanov, Alexander L., 238
Kounadi, Evangelia, 370
Kowalczyk, Tomasz H., 327
Kracht, Lutz W., 453
Kriz, Jasna, 434
Kruczynski, Anna, 446
Lackas, Christian, 295
Lan, Xiaoli, 227
Lang, Juntao, 227
Laverman, Peter, 144
Le Pape, Alain, 446
Leconge, Rémy, 446
Ledée, Roger, 446
Lee, Seulki, 3
Lenkinski, Robert E., 295
Lepin, Eric J., 168
Lerondel, Stéphanie, 446
Leung, Matthew, 69
Lewis, Jason S., 177
Li, Chun, 28
Li, Cong, 359
Li, Congjiao, 227
Li, Qingpo, 43
Li, Shihong, 177
Li, Zibo, 284
Limouris, Georgios, 370
Lin, Wei-Yu, 168
Liu, Fangbing, 295
Liu, Kai, 278
Liu, Kan, 168
Liu, Shuang, 386
Liu, Xuewu, 56
Liu, Zhaofei, 278
Lunsford, Elaine P., 295
Ma, Xibo, 278
Mach, Robert H., 420
Mack, Aaron, 43
Makris, Nikolaos, 370
Maldonado, Rafael, 481
Mallidi, Srivalleesha, 102
Marinopoulos, Spyridon, 370
Martinez, Jonathan O., 56
Martín-García, Elena, 481
Masutani, Yoshitaka, 317
Mathejczyk, Julia Eva, 469
McShane, Matthew, 327
Mees, Gilles, 340
Mehrmohammadi, Mohammad, 102
Melancon, Marites P., 28
Millán, Olga, 481
Mok, Hyejung, 69
Morgan, Desiree E., 153
Motekallemi, Arash, 248
Mustafi, Devkumar, 177
Napp, Joanna, 469
Nasr, Khaled A., 91
Nemati, Fariba, 135
Ni, Yicheng, 359
Normand, Guillaume, 177
Oh, Junghwan, 102
Ohtomo, Kuni, 317, 377
Olma, Sebastian, 168
Oltenfreiter, Ruth, 340
Oyen, Wim J.G., 144
Padegimas, Linas, 327
Papantoniou, Vassilios, 370
Pareto, Deborah, 481
Park, James O., 69
Passon, Marta, 81
Patil, Abhay V., 238
Pauli, Jutta, 258, 469
Peces-Barba, Germán, 398
Peeters, Marc, 340
Pelizzari, Charles A., 177
Pérez-Rial, Sandra, 398
Pesnel, Sabrina, 446
Phelps, Michael E., 168
Pillon, Arnaud, 446
Pleijhuis, Rick G., 248
Ptohis, Nikolaos, 370
Qin, Chenghu, 278
Qiu, Yiru, 359
Ratanakanit, Harnprasopwat, 377
Resch-Genger, Ute, 258, 469
Reutelingsperger, Chris, 340
Reynolds, Fred, 407
Richter, Raphaela, 197
Rojas, Santiago, 481
Roney, Celeste A., 305
Rothfuss, Justin M., 420
Ruggiero, Alessandro, 177
Rychak, Joshua J., 238
Sauer, Heinrich, 197
Schroeter, Michael, 453
Sellers, Jeffery C., 153
Serda, Rita E., 43
Serganova, Inna, 215
Serra, Miquel Àngel, 481
Shahinian, Tony, 284
Shen, Clifton K.-F., 168
Sheng, Fugeng, 377
Shi, Jiyun, 386
Shimada, Morio, 317
Siclovan, Tiberiu M., 91
Sirk, Shannon J., 168
Socher, Ines, 81
Sotiropoulou, Evangelia, 370
Sotiropoulou, Maria, 370
Stafford, Susan J., 43
Stephen, Zachary, 69
Stockard, Cecil R., 153
Streeter, Jason E., 460
Summers, Ronald M., 305
Sun, Conroy, 69
Sutcliffe, Julie L., 1
Swierczewska, Magdalena, 3
Syrgiannis, Konstantinos, 370
Tan Hehir, Cristina A., 91
Tanaka, Takemi, 43
Tanter, Mickael, 135
Tasciotti, Ennio, 56
Teng, Gao-Jun, 359
Thorek, Daniel L.J., 206
Tian, Jie, 278
Tietze, Lutz-F., 469
Tojo, Arinobu, 377
Torchilin, Vladimir P., 43
Tretiakova, Maria, 177
Tsaroucha, Angeliki, 370
Tseng, Hsian-Rong, 168
Tsiouris, Spyridon, 370
Tsourkas, Andrew, 206
Tsuruta, James, 460
Ullrich, Roland T., 453
Valsamaki, Pipitsa, 370
van Dam, Gooitzen M., 248
van Dam, R. Michael, 168
Van Damme, Nancy, 340
van de Ven, Anne, 43
Van de Wiele, Christophe, 340
van der Zee, Ate G.J., 248
van Oosten, Marleen, 248
Vangestel, Christel, 340
Vangveravong, Suwanna, 420
Veiseh, Omid, 69
Vider, Jelena, 215
Vollmar, Stefan, 453
Wang, Fan, 278
Wang, Ming-Wei, 168
Wartenberg, Maria, 197
Watanabe, Makoto, 317, 377
Weatherspoon, Marcy R., 327
Weisshaar, Christine L., 206
Weng, Yuan-Cheng, 434
Wenzel, Matthias, 81
Wierwille, Jeremiah, 305
Wiktorowicz, John E., 43
Winkeler, Alexandra, 197
Winkelstein, Beth A., 206
Wu, Anna M., 168
Xie, Jianwu, 305
Xu, Biying, 305
Xu, Jinbin, 420
Yang, Xin, 278
Yang, Yongliang, 123
Ye, Zhaohui, 111
Yoshikawa, Kohki, 317
Yuan, Shuai, 305
Yurek, David M., 327
Zamora, Marta A., 177
Zeng, Chenbo, 420
Zhang, Bo, 278
Zhang, Miqin, 69
Zhang, Yongxue, 227
Zhao, Xing-Zhong, 168
Zhou, Yang, 386
Zhu, Shouping, 278
Ziady, Assem G., 327
Zinn, Kurt R., 153